Endotoxin-trained neutrophils reprogrammed to fight tumors
This technology takes ordinary neutrophils — white blood cells that typically suppress immune responses against tumors — and reprograms them into cancer fighters by exposing them to a very small, non-toxic dose of endotoxin (a bacterial molecule). The treated neutrophils shift their surface protein profile in a specific, measurable way that makes them stop suppressing the immune system and instead help T cells attack cancer. The researchers identified the molecular switches involved (STAT5 activation and IRAK-M reduction), giving a clear mechanistic handle for manufacturing these cells. The result is a defined cell therapy product: donor neutrophils collected, trained in a lab, and infused into cancer patients to boost their immune response.
What you could build
An allogeneic cell therapy product — donor-derived, endotoxin-trained neutrophils — manufactured and infused into cancer patients as a standalone or combination immunotherapy; likely buyers are oncology-focused cell therapy companies, hospital cell therapy manufacturing centers, and pharmaceutical firms with existing immuno-oncology pipelines.
Who in Virginia should care
Virginia-based biotech firms, Inova or UVA Health cell therapy programs, and defense-adjacent biomedical contractors (BARDA/DARPA-funded oncology) would have plausible interest.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Liwu Li, Yao Zhang
- Filed
- Patent pending — filed January 3, 2025
- Status
- Application
- Publication number
- US20250223555A1
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology. Email us for an introduction prosim@harbor.capital.
Prosim summaries are generated from public patent text and are not legal advice.